Lexicon Pharmaceutical’s investigative agent LX1032 has been granted fast-track status by the United States Food and Drug Administration (FDA).
LX1032 is an inhibitor of tryptophan hydroxylase (HTP), a target identified through the Genome5000™ program. Excessive levels of serotonin have been associated with carcinoid syndrome symptoms, and HTP is a rate-limiting enzyme in the synthesis of serotonin. Preclinical studies have demonstrated that LX1032 reduced peripheral serotonin and urinary 5HIAA (a breakdown product of serotonin) without affecting serotonin levels in the brain.
LX1032 has completed Phase Ia studies; Lexicon is awaiting results.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
